Holen Sie sich die Stockscreener-App
14.17
2.61%
-0.38
Handel nachbörslich:
14.56
0.39
+2.75%
Schlusskurs vom Vortag:
$14.55
Offen:
$14.36
24-Stunden-Volumen:
123.12K
Relative Volume:
0.21
Marktkapitalisierung:
$7.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.60M
KGV:
-4.4842
EPS:
-3.16
Netto-Cashflow:
$-8.96M
1W Leistung:
-11.82%
1M Leistung:
+145.47%
6M Leistung:
+96.81%
1J Leistung:
+69.90%
1-Tages-Spanne:
$12.67
$14.73
1-Wochen-Bereich:
$12.67
$16.97
52-Wochen-Spanne:
$4.9176
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
Firmenname
Artelo Biosciences Inc
Sektor
Branche
Telefon
858-925-7049
Adresse
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Vergleichen Sie ARTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
14.17 | 11.32M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Eingeleitet | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Aktie (ARTL) Neueste Nachrichten
Artelo Biosciences Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com
What analysts say about Artelo Biosciences Inc. stockConsistently superior profits - jammulinksnews.com
What drives Artelo Biosciences Inc. stock priceRobust investment performance - jammulinksnews.com
What makes Artelo Biosciences Inc. stock price move sharplyStable Stocks With High Yield - Newser
Artelo Biosciences Announces $6.5 Million At-The-Market Offering Agreement - AInvest
Is Artelo Biosciences Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
Artelo Biosciences' ATM Offering: A Delicate Balance Between Liquidity and Dilution - AInvest
Artelo Biosciences Announces At-The-Market Offering Agreement - TipRanks
What analysts say about Artelo Biosciences Inc. stock outlookMinimized Risk Maximum Return - Newser
Why Artelo Biosciences Inc. stock attracts strong analyst attentionFree Join Group - Newser
How Artelo Biosciences Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
Artelo Biosciences Plummets Over 22%—What's Driving the Freefall? - AInvest
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Artelo Biosciences Shares Climb on Promising Preclinical Osteoarthritis Pain Data - MSN
Artelo Biosciences Plans to Offer 920K Shares of Common Stock - AInvest
Artelo Biosciences completes reverse stock split and reports preliminary Q2 financials - Investing.com Nigeria
D. Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Buy - Defense World
D Boral Capital Upgrades Artelo Biosciences (NASDAQ:ARTL) to Strong-Buy - Defense World
Artelo Biosciences presents positive data for arthritis pain drug By Investing.com - Investing.com South Africa
Artelo Biosciences stock soars after positive preclinical pain data By Investing.com - Investing.com Nigeria
Artelo Biosciences stock soars after positive preclinical pain data - Investing.com
Artelo Biosciences Announces Positive Preclinical Efficacy Data for Art26.12 in Osteoarthritis Pain At the 35Th Annual International Cannabinoid Research Society Symposium - MarketScreener
Artelo Biosciences announces preclinical efficacy results of ART26.12 - TipRanks
Artelo Biosciences Soars 30.5% on Promising Depression Drug Data - AInvest
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium - The Manila Times
Artelo Biosciences presents positive data for arthritis pain drug - Investing.com
Artelo Biosciences Presents Preclinical Data on ART26.12 as Potential Non-Opioid Treatment for Osteoarthritis Pain at ICRS Symposium - Nasdaq
Breakthrough Pain Drug Matches Naproxen Efficacy Without Opioid Side Effects in Latest Trial - Stock Titan
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Insider Monkey
Finanzdaten der Artelo Biosciences Inc-Aktie (ARTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):